12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) […]
Rahway, NJ., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines. If the European Commission (EC) adopts the recommendation, the […]
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA […]
The leading manufacturer of otic treatments expands portfolio with the only FDA-approved, one dose, in-clinic treatment for Pseudomonas aeruginosa and other pathogens RAHWAY, N.J., May 02, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of MOMETAMAX SINGLE™ […]
Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products Rahway, N.J., February 11, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that S&P Global Animal Health awarded the injectable formulation of BRAVECTO® (fluralaner) the 2024 Best New Companion […]
The new formulation targets internal and external parasites, expanding the BRAVECTO® portfolio Rahway, NJ, – November 26, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission has granted the marketing authorization for BRAVECTO® TriUNO, a new formulation of BRAVECTO (fluralaner) for dogs that targets […]
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease RAHWAY, N.J., June 25, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the USDA approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of […]
Rahway, NJ., March 18, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK) has announced a continued commitment to rabies elimination through a donation of NOBIVAC® rabies vaccines to the Mission Rabies program, a charity initiative of the Worldwide Veterinary Service (WVS). The donations will continue over the […]
BRAVECTO eliminated kennel infestations of brown dog ticks (Rhipicephalus sanguineus sensu lato) External imidacloprid/flumethrin collar treatments failed to eliminate all ticks from kennels RAHWAY, N.J., March 15, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the publication of a recent study demonstrating the efficacy of […]
BRAVECTO rapidly and consistently kills Ixodes scapularis ticks, a vector of the pathogen responsible for Lyme Disease, as compared to Simparica TRIO® RAHWAY, N.J., February 2, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the publication of a recent study demonstrating BRAVECTO® (fluralaner) Chews for […]